Long-term Effect of Gefitinib (ZD1839) on Squamous Cell Carcinoma of the Lung

Toshiyuki Kozuki, Katsuyuki Kiura, Hiroshi Ueoka, Masahiro Tabata, Hiroshi Date, Shuji Hamazaki, Akihiro Bessho, Mitsune Tanimoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This case report describes the effects of long-term treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib ('Iressa', ZD1839) on a patient with squamous cell carcinoma of the lung. Gefitinib is an orally active agent that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and host-dependent processes that promote tumor growth. A 62-year-old Japanese man with a history of heavy smoking was diagnosed with squamous cell carcinoma of the lung, clinical stage IIIB (T4N3M0), in August 2000. He received two cycles of cisplatin-based chemotherapy and subsequently underwent left upper lobectomy followed by thoracic radiotherapy. After these treatments, he underwent partial lobectomy and pneumonectomy because of disease recurrence. In June 2002, he started treatment with gefitinib 250 mg/day orally because of mediastinal lymph node recurrence and an elevated serum cytokeratin 19 fragment (CYFRA) level. As a result, the mediastinal lymph node markedly regressed and the serum CYFRA level became normalized. Although he experienced recurrence three times during the 18 months prior to treatment with gefitinib, recurrence has not been experienced in the 13 months since the start of gefitinib treatment, while tolerability has been acceptable.

Original languageEnglish
Pages (from-to)393-396
Number of pages4
JournalAnticancer Research
Volume24
Issue number1
Publication statusPublished - Jan 2004

Fingerprint

Squamous Cell Carcinoma
Lung
Keratin-19
Recurrence
Lymph Nodes
Therapeutics
Pneumonectomy
gefitinib
Serum
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Cisplatin
Signal Transduction
Neoplasms
Cell Survival
Radiotherapy
Thorax
Smoking
Drug Therapy
Growth

Keywords

  • EGFR
  • EGFR-TKI
  • Gefitinib
  • NSCLC
  • Squamous
  • ZD1839

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kozuki, T., Kiura, K., Ueoka, H., Tabata, M., Date, H., Hamazaki, S., ... Tanimoto, M. (2004). Long-term Effect of Gefitinib (ZD1839) on Squamous Cell Carcinoma of the Lung. Anticancer Research, 24(1), 393-396.

Long-term Effect of Gefitinib (ZD1839) on Squamous Cell Carcinoma of the Lung. / Kozuki, Toshiyuki; Kiura, Katsuyuki; Ueoka, Hiroshi; Tabata, Masahiro; Date, Hiroshi; Hamazaki, Shuji; Bessho, Akihiro; Tanimoto, Mitsune.

In: Anticancer Research, Vol. 24, No. 1, 01.2004, p. 393-396.

Research output: Contribution to journalArticle

Kozuki, T, Kiura, K, Ueoka, H, Tabata, M, Date, H, Hamazaki, S, Bessho, A & Tanimoto, M 2004, 'Long-term Effect of Gefitinib (ZD1839) on Squamous Cell Carcinoma of the Lung', Anticancer Research, vol. 24, no. 1, pp. 393-396.
Kozuki, Toshiyuki ; Kiura, Katsuyuki ; Ueoka, Hiroshi ; Tabata, Masahiro ; Date, Hiroshi ; Hamazaki, Shuji ; Bessho, Akihiro ; Tanimoto, Mitsune. / Long-term Effect of Gefitinib (ZD1839) on Squamous Cell Carcinoma of the Lung. In: Anticancer Research. 2004 ; Vol. 24, No. 1. pp. 393-396.
@article{42956ea6509f43588d274551a045b096,
title = "Long-term Effect of Gefitinib (ZD1839) on Squamous Cell Carcinoma of the Lung",
abstract = "This case report describes the effects of long-term treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib ('Iressa', ZD1839) on a patient with squamous cell carcinoma of the lung. Gefitinib is an orally active agent that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and host-dependent processes that promote tumor growth. A 62-year-old Japanese man with a history of heavy smoking was diagnosed with squamous cell carcinoma of the lung, clinical stage IIIB (T4N3M0), in August 2000. He received two cycles of cisplatin-based chemotherapy and subsequently underwent left upper lobectomy followed by thoracic radiotherapy. After these treatments, he underwent partial lobectomy and pneumonectomy because of disease recurrence. In June 2002, he started treatment with gefitinib 250 mg/day orally because of mediastinal lymph node recurrence and an elevated serum cytokeratin 19 fragment (CYFRA) level. As a result, the mediastinal lymph node markedly regressed and the serum CYFRA level became normalized. Although he experienced recurrence three times during the 18 months prior to treatment with gefitinib, recurrence has not been experienced in the 13 months since the start of gefitinib treatment, while tolerability has been acceptable.",
keywords = "EGFR, EGFR-TKI, Gefitinib, NSCLC, Squamous, ZD1839",
author = "Toshiyuki Kozuki and Katsuyuki Kiura and Hiroshi Ueoka and Masahiro Tabata and Hiroshi Date and Shuji Hamazaki and Akihiro Bessho and Mitsune Tanimoto",
year = "2004",
month = "1",
language = "English",
volume = "24",
pages = "393--396",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Long-term Effect of Gefitinib (ZD1839) on Squamous Cell Carcinoma of the Lung

AU - Kozuki, Toshiyuki

AU - Kiura, Katsuyuki

AU - Ueoka, Hiroshi

AU - Tabata, Masahiro

AU - Date, Hiroshi

AU - Hamazaki, Shuji

AU - Bessho, Akihiro

AU - Tanimoto, Mitsune

PY - 2004/1

Y1 - 2004/1

N2 - This case report describes the effects of long-term treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib ('Iressa', ZD1839) on a patient with squamous cell carcinoma of the lung. Gefitinib is an orally active agent that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and host-dependent processes that promote tumor growth. A 62-year-old Japanese man with a history of heavy smoking was diagnosed with squamous cell carcinoma of the lung, clinical stage IIIB (T4N3M0), in August 2000. He received two cycles of cisplatin-based chemotherapy and subsequently underwent left upper lobectomy followed by thoracic radiotherapy. After these treatments, he underwent partial lobectomy and pneumonectomy because of disease recurrence. In June 2002, he started treatment with gefitinib 250 mg/day orally because of mediastinal lymph node recurrence and an elevated serum cytokeratin 19 fragment (CYFRA) level. As a result, the mediastinal lymph node markedly regressed and the serum CYFRA level became normalized. Although he experienced recurrence three times during the 18 months prior to treatment with gefitinib, recurrence has not been experienced in the 13 months since the start of gefitinib treatment, while tolerability has been acceptable.

AB - This case report describes the effects of long-term treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib ('Iressa', ZD1839) on a patient with squamous cell carcinoma of the lung. Gefitinib is an orally active agent that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and host-dependent processes that promote tumor growth. A 62-year-old Japanese man with a history of heavy smoking was diagnosed with squamous cell carcinoma of the lung, clinical stage IIIB (T4N3M0), in August 2000. He received two cycles of cisplatin-based chemotherapy and subsequently underwent left upper lobectomy followed by thoracic radiotherapy. After these treatments, he underwent partial lobectomy and pneumonectomy because of disease recurrence. In June 2002, he started treatment with gefitinib 250 mg/day orally because of mediastinal lymph node recurrence and an elevated serum cytokeratin 19 fragment (CYFRA) level. As a result, the mediastinal lymph node markedly regressed and the serum CYFRA level became normalized. Although he experienced recurrence three times during the 18 months prior to treatment with gefitinib, recurrence has not been experienced in the 13 months since the start of gefitinib treatment, while tolerability has been acceptable.

KW - EGFR

KW - EGFR-TKI

KW - Gefitinib

KW - NSCLC

KW - Squamous

KW - ZD1839

UR - http://www.scopus.com/inward/record.url?scp=1442301615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442301615&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 393

EP - 396

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -